185315-52-0 Usage
General Description
3-Chloro-2-pyridineacetonitrile is a chemical compound with the molecular formula C7H4N2Cl. It is a pale yellow solid that is soluble in organic solvents, but only sparingly soluble in water. 3-Chloro-2-pyridineacetonitrile is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceutical drugs and agrochemicals. Its applications include the production of anti-inflammatory drugs, anti-cancer agents, and other therapeutic compounds. It is also used as a building block in the synthesis of pyridine derivatives and heterocyclic compounds. Additionally, 3-Chloro-2-pyridineacetonitrile has potential applications in the field of material science and organic synthesis. Due to its versatile properties and wide range of applications, this chemical compound is of significant interest to researchers and manufacturers in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 185315-52-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,5,3,1 and 5 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 185315-52:
(8*1)+(7*8)+(6*5)+(5*3)+(4*1)+(3*5)+(2*5)+(1*2)=140
140 % 10 = 0
So 185315-52-0 is a valid CAS Registry Number.
185315-52-0Relevant articles and documents
UREA DERIVATIVES AND USES THEREOF
-
Paragraph 00561, (2015/01/09)
The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
N-[2-(2-Pyridinyl)ethyl]benzamide compounds and their use as fungicides
-
Page 28-29, (2010/02/10)
Compound of general formula (I): Process for preparing this compound. Fungicidal composition comprising a compound of general formula (I). Method for treating plants by applying a compound of general formula (I) or a composition comprising it.